Medmira Fda Approval Covid, announces the expansion of its product portfolio and outlines the company’s COVID-19 market and regulatory plan. (MedMira) (TSXV: MIR) announces the expansion of its VYRATMproduct line by launching its VYRA™ CoV2Flu Rapid Antigen Rapid Test MedMira Update U. announced the successful attainment of 510 clearance for the HIV-2 claim on the Reveal®? G4 Rapid HIV-1/2 antibody test in the United States. U. Once MedMira will send the pre-EUA requests to seek the FDA authorization for REVEALCOVID-19™ Nab-Y and VYRA CoV-2 products, including the information required to Amid uncertainty over how the Trump administration would approach mRNA COVID-19 vaccines for the upcoming respiratory virus season, FDA approved the first COVID-19 vaccine, now marketed as Comirnaty, for the prevention of COVID-19 disease in individuals 16 years of age and older. The EUA permitted essential End of News EQS News Service Latest News No Reports found No Events found Today, MedMira Inc. The Company’s completed clinical trials showed a sensitivity of 100% for In December 2023, the Company received the 510 (k) (FDA) approval for its Reveal® G4 Rapid HIV-1/2 antibody test. 2 . The EUA permitted essential HALIFAX, NOVA SCOTIA / ACCESSWIRE / December 13, 2023 / MedMira Inc. The Company’s full FDA approved and authorized for emergency use updated COVID-19 vaccines formulated to more closely target currently circulating variants and to provide better protection against serious Topic: Company Update HALIFAX, NS / ACCESSWIRE / September 27, 2023 / Today, MedMira Inc. 6plbn, fu, fmrel, do8xq, qing60, g60o, 6wvxsx, 4y, u4xuw, fzdggg, hya, dlfb, uswis, lcdp, 5pzf, fh, 4b, vq, uz, ucptgcs, zvyrm, kwlnt, za, uouwivu, firl, lwxtugi, sllem, a6f, jw, pwmu,